Health Canada approves Biocon and Mylan’s Ogivri, the first Trastuzumab Biosimilar, for the treatment of HER2-positive Breast and Gastric Cancers
Wednesday, May 22, 2019 | DrugName : trastuzumab biosimilar [sg_popup id=”2993″ event=”inherit”][/sg_popup]Biocon Ltd. and Mylan N.V. announced that Health Canada
Read More